Port Machinery

Business

Microsoft's AI Ambitions Fuel Record Cloud Revenue, But Heavy Spending Weighs on Shares

Microsoft posts record cloud and AI-driven revenue for Q2, fueled by new partnerships and its custom AI chip. However, a significant surge in capital expenditures for AI infrastructure and a slight deceleration in Azure growth triggered the stock's worst single-day drop since 2020, testing investor resolve on the long-term payoff.

Jan 30, 2026

Business

Amundi's Revised Price Target Sparks Investor Reassessment Amid Shifting Market Sentiment

A fresh round of analyst price target adjustments for European asset manager Amundi (ENXTPA:AMUN) is prompting investors to recalibrate their expectations, placing renewed scrutiny on the firm's growth trajectory in a challenging macroeconomic climate.

Jan 30, 2026

Business

Cardinal Energy Secures CA$95M in Upsized Equity Financing to Fuel Reford 2 Project and Trim Debt

Cardinal Energy Ltd. (TSX:CJ) has successfully upsized its bought deal financing to CA$95.15 million, capitalizing on robust investor appetite. The proceeds are earmarked to accelerate development of its key Reford 2 thermal oil project and strengthen its balance sheet, even as its valuation metrics present a complex picture for investors.

Jan 30, 2026

Business

DuPont Unveils AmberLite FPA57 Resin, Targeting Efficiency Gains in Key Industries

DuPont de Nemours launches a new ion exchange resin designed to boost productivity for organic acid producers in food, pharma, and bioplastics, as its stock shows sustained momentum.

Jan 30, 2026

Business

Unity Integrates Coda for Direct Web Stores, Aiming to Reshape Developer Monetization

Unity Software's new in-app web store integration with Coda could empower developers to bypass traditional marketplace fees, potentially altering the company's revenue streams and addressing its persistent valuation gap amid volatile stock performance.

Jan 30, 2026

Business

Bitcoin's Luster Fades Against Gold, Revisiting 2017 Ratio as Debate Over Digital Haven Intensifies

The Bitcoin-to-gold ratio has slumped close to its 2017 level, fueling a fresh round of scrutiny over the cryptocurrency's viability as a long-term store of value amidst a resurgent precious metals market and persistent macroeconomic uncertainty.

Jan 30, 2026

Business

Visa Posts Strong Q1 Results as Consumer Spending Holds Steady, Digital Services Fuel Growth

Visa's fiscal first-quarter earnings surpassed expectations, driven by robust cross-border transactions and a surge in high-margin digital services. The payments giant signals confidence in sustained consumer resilience despite some moderation in U.S. debit volumes.

Jan 30, 2026

Business

Schneider National Navigates Tough Q4 as Freight Demand Falters, Eyes Supply-Driven Recovery

Schneider National's Q4 2025 earnings fell short of expectations, pressured by a sharp late-year drop in freight demand and severe weather. While acknowledging near-term challenges, executives pointed to early signs of market normalization and detailed strategic cost actions aimed at positioning the carrier for an eventual upcycle.

Jan 30, 2026

Business

Freedom Capital Trims Li Auto Target Amid Intensifying China EV Price War

Freedom Capital Markets has lowered its price target for Li Auto (NASDAQ: LI) from $34 to $25, citing a mixed quarterly performance and a challenging outlook as China's electric vehicle sector grapples with a fierce price war and softening demand.

Jan 30, 2026

Business

BofA Doubles Down on Hesai Group, Boosts Price Target on Lidar Leadership and Regulatory Tailwinds

Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.

Jan 30, 2026

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Jan 30, 2026

Business

Macquarie Trims XPeng Target, Citing Subsidy Cuts and 'Transition Year' Challenges

Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.

Jan 30, 2026

Business

Atour Emerges as a Premium Contender in China's Hotel Wars, Says CLSA

Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.

Jan 30, 2026

Business

Morgan Stanley Bullish on Full Truck Alliance, Sees 30%+ Transaction Revenue Surge by 2026

Despite a mixed analyst outlook, Morgan Stanley projects robust growth for Full Truck Alliance's core commission business, even as overall revenue faces headwinds. The digital freight platform's long-term strategy is gaining favor.

Jan 30, 2026

Business

Macquarie Upgrades NIO to Outperform on Strong Q4 Sales, Battery Service Adoption

Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.

Jan 30, 2026

Business

Regulatory Headwinds Cloud Outlook for PDD Holdings Amid Broader China Internet Crackdown

While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Jan 30, 2026

Business

Goldman Sachs Upgrades BioNTech to Buy, Citing Oncology Pipeline as Key Growth Driver

Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.

Jan 30, 2026

Business

UBS Sees Stabilization for Globant in 2026, Raises Price Target Amid Mixed Outlook

UBS has increased its price target for digital transformation leader Globant to $75, forecasting a period of stabilized, if modest, growth for the IT services sector next year despite near-term revenue headwinds.

Jan 30, 2026